Filgotinib FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 27, 2019.
FDA Approved: No
Generic name: filgotinib
Company: Gilead Sciences, Inc.
Treatment for: Rheumatoid Arthritis
Filgotinib is an oral, selective JAK1 inhibitor in development for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA).
Development timeline for filgotinib
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.